This $236,292 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to isolate and characterize the structure of HSV glycoprotein complexes relevant to virus entry. The 2-year project led by Tufts University School of Medicine aims to use antibodies and non-detergent extraction methods to stabilize and isolate the GD/GH/GL and GH/GL/GB glycoprotein complexes,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $318,085 to support research on the role of antibodies in controlling virus infections through Fc-dependent mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytolysis (CDC). The research aims to elucidate the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research on manipulating the DNA damage response and proteome on viral genomes during herpes simplex virus (HSV) infection. The $651,832 award, with a project period from November 2024 to October 2029, will enable researchers at The Children's Hospital of Philadelphia to conduct a multi-modal proteomic...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,700.00 to New York University School of Medicine to conduct research focused on improving HIV vaccine design. The key goals are to: 1) Design and validate an immunogen targeting the V2B neutralization epitope on the HIV/SIV viral spike, and 2) Test the combination of vaccine-elicited anti-V2B...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $340,712 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Rochester. The grant, titled "Evaluating the Role of Monocytes in the Development of an Effective HIV Vaccine Response", aims to investigate the role of monocyte subpopulations in regulating the antibody response to HIV vaccines. The research project, scheduled for completion by June 30, 2027,...
This federal Project Grant award of $462,000.00 was issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will support research at Albert Einstein College of Medicine in Bronx, NY to design improved T cell epitopes for enhancing T cell vaccines and therapies. The research aims to use molecular dynamic simulation and functional in vitro/in vivo assays to define key molecular and TCR/epitope...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $13,946,446 Cooperative Agreement titled "PROVIDENT: PREPOSITIONING OPTIMIZED STRATEGIES FOR VACCINES AND IMMUNOTHERAPEUTICS AGAINST DIVERSE EMERGING INFECTIOUS THREATS" to the Albert Einstein College of Medicine. The overarching goal of this 5-year project is to deliver "plug-and-play" vaccine and therapeutic antibody...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,620 to Albert Einstein College of Medicine to develop broadly protective human monoclonal antibody therapies against alphaviruses. The key goals are to: 1) engineer Fc mutations to enhance the in vitro and in vivo properties of broadly neutralizing antibodies, 2) perform viral escape studies to define mechanisms...
The federal Project Grant award R01AI187016 for $737,761.00, awarded on August 1, 2024 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to enhance HIV prevention through a vaccine approach that promotes durable immunity. The key objectives are to induce robust CD4 T follicular helper (TFH) cells, which are essential for vigorous B cell activity within germinal centers, to facilitate the...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,486,800 to the Albert Einstein College of Medicine to investigate the role of TNFRSF14 signaling in promoting antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against herpes simplex virus (HSV). The researchers engineered a novel single-cycle HSV vaccine strain and isolated protective monoclonal antibodies that mediate ADCC rather than virus neutralization. They found that TNFRSF14 signaling is critical for ADCC activity and plan to further characterize the pathways and structural determinants that promote FCGR activation. The results aim to inform new strategies for future vaccine and monoclonal antibody design against infectious diseases.